PD-L1 TPS ≥50%
1 drugsPredictive biomarker for patient selection in 7 indications
1
Approved Drugs
7
Indications
1
Companies
PD-L1 TPS ≥50% is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 7 indications including Metastatic cutaneous squamous cell carcinoma, Locally advanced cutaneous squamous cell carcinoma, Adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 TPS ≥50% drugs below.
Search PD-L1 TPS ≥50% Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-L1 TPS ≥50%
| Drug | Company | Therapeutic Area |
|---|---|---|
| LIBTAYO | Regeneron | Oncology |
PD-L1 TPS ≥50% Indications
Metastatic cutaneous squamous cell carcinoma Locally advanced cutaneous squamous cell carcinoma Adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation Locally advanced basal cell carcinoma Metastatic basal cell carcinoma First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with platinum-based chemotherapy First-line monotherapy for locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression (TPS ≥50%)